

VPA23462/003/001

**Bupaq Multidose 0.3 mg/ml Solution for Injection for Dogs and Cats**

<b>Variation</b>	<b>Summary</b>	<b>Date</b>
Vet - C1	VNRA - Vet - C1 - Change(s) in the name or address or contact details of a qualified person for pharmacovigilance (QPPV) - C1 Changes to the safety, efficacy and pharmacovigilance part of the dossier: Change(s) in the name or address or contact details of a qualified person for pharmacovigilance (QPPV)	07/04/25
Vet - B3 s)	VNRA - Vet - B3 s) - s) Deletion of a supplier of packaging components or devices - B3 s) Changes to the quality part of the dossier: Deletion of a supplier of packaging components or devices (when mentioned in the dossier)	13/01/25
Vet - C6	VNRA - Vet - C6 - Introduction of a summary of the PSMF or changes to the summary of the PSMF not already covered elsewhere in the Annex to Regulation (EU) 2021/17 - C6 Changes to the safety, efficacy and pharmacovigilance part of the dossier: Introduction of a summary of the PSMF or changes to the summary of the PSMF not already covered elsewhere in the Annex to Regulation (EU) 2021/17	26/05/23
Vet - A1 e)	VNRA - Vet - A1 e) - e) Change in the name or address or contact details of a manufacturer or importer of the finished product (including batch release or quality control testing sites) - A1 e) Administrative changes: Change in the name or address or contact details of a manufacturer or importer of the finished product (including batch release or quality control testing sites)	26/05/23
Vet - B44	VNRA - Vet - B44 - Submission of a new or updated Ph. Eur. CEP from an already approved manufacturer for a non-sterile active substance, starting material, reagent or intermediate, excipient - B44 Changes to the quality part of the dossier: Submission of a new or updated Ph. Eur. CEP from an already approved manufacturer for a non-sterile: — active substance; — starting material, reagent or intermediate used in the manufacturing process of the active substance; — excipient	16/12/22